In a phase I study, ceritinib was administered to 114 ALK-rearranged, crizotinib-naïve and -resistant NSCLC patients [45] achieving an ORR of 58%, and demonstrating activity also in those patients with ALK gene amplification or mutations (L1196 M, S1206Y) developed after crizotinib therapy. Here, ALK is linked to non-small cell lung carcinoma.